Shir-jing K. Ho

St George & Sutherland Clinical School
Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Journal: EJHaem

Published: May 09, 2024

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

Journal: Blood advances

Published: May 08, 2023

Environmental impact of high-flow nasal oxygenation.

Environmental impact of high-flow nasal oxygenation.

Journal: Anaesthesia

Published: December 06, 2022

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.

Journal: Blood advances

Published: December 02, 2022

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 13, 2021

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 01, 2021

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.

Journal: British journal of haematology

Published: May 09, 2020

Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery.

Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery.

Journal: Canadian journal of kidney health and disease

Published: November 21, 2019

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Journal: Haematologica

Published: August 11, 2016

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).

Journal: Leukemia & lymphoma

Published: June 09, 2016

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

Journal: Blood

Published: March 03, 2015

Prevalence of depression in patients referred with snoring and obstructive sleep apnoea.

Prevalence of depression in patients referred with snoring and obstructive sleep apnoea.

Journal: Internal medicine journal

Published: December 02, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026